AR046762A1 - Hormonas de administracion transdermica que no necesitan potenciadores de penetracion - Google Patents

Hormonas de administracion transdermica que no necesitan potenciadores de penetracion

Info

Publication number
AR046762A1
AR046762A1 ARP040104605A ARP040104605A AR046762A1 AR 046762 A1 AR046762 A1 AR 046762A1 AR P040104605 A ARP040104605 A AR P040104605A AR P040104605 A ARP040104605 A AR P040104605A AR 046762 A1 AR046762 A1 AR 046762A1
Authority
AR
Argentina
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
ARP040104605A
Other languages
English (en)
Inventor
Thomas Langguth
Stefan Bracht
Michael Dittgen
Petra Hubert
Dirk Schenk
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046762(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR046762A1 publication Critical patent/AR046762A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeacion en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que consiguen durante todo un periodo de al menos 1 semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semana. Composición, kit, método de tratamiento.
ARP040104605A 2003-12-12 2004-12-10 Hormonas de administracion transdermica que no necesitan potenciadores de penetracion AR046762A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078881 2003-12-12

Publications (1)

Publication Number Publication Date
AR046762A1 true AR046762A1 (es) 2005-12-21

Family

ID=34924031

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104605A AR046762A1 (es) 2003-12-12 2004-12-10 Hormonas de administracion transdermica que no necesitan potenciadores de penetracion

Country Status (24)

Country Link
EP (2) EP1541137B1 (es)
CN (1) CN101843603B (es)
AR (1) AR046762A1 (es)
AT (1) ATE457168T1 (es)
CR (1) CR8465A (es)
CY (2) CY1110637T1 (es)
DE (1) DE602004025444D1 (es)
DK (2) DK2138169T3 (es)
ES (2) ES2340925T3 (es)
GT (1) GT200400262A (es)
HK (2) HK1074801A1 (es)
HN (1) HN2004000526A (es)
HR (2) HRP20100254T1 (es)
JO (1) JO2606B1 (es)
ME (1) ME01069B (es)
MY (2) MY144053A (es)
PE (1) PE20051035A1 (es)
PL (2) PL1541137T3 (es)
PT (2) PT1541137E (es)
RS (2) RS51260B (es)
SI (2) SI1541137T1 (es)
SV (1) SV2006001970A (es)
TW (1) TWI257299B (es)
UA (1) UA89766C2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219030B1 (pl) 2003-02-21 2015-03-31 Schering Ag Transdermalny system terapeutyczny w postaci plastra odporny na działanie promieniowania UV
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US9198920B2 (en) 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
PT2613772T (pt) 2010-09-06 2017-03-06 Bayer Ip Gmbh Emplastros transdérmicos de dose baixa com alta libertação de fármaco
US20130195956A1 (en) * 2012-01-27 2013-08-01 Agile Therapeutics, Inc. Transdermal Hormone Delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081537A (en) 1975-10-10 1978-03-28 Schering Aktiengesellschaft Δ15 -Steroids and pharmaceutical compositions thereof
EP0573133A1 (de) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Mittel zur transdermalen Applikation das Gestoden enthält
AU657502B2 (en) 1990-10-29 1995-03-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE60043621D1 (de) 1999-11-24 2010-02-11 Agile Therapeutics Inc Verbessertes transdermales verabreichungssystem zur empfängnisverhütung und verfahren
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use

Also Published As

Publication number Publication date
JO2606B1 (en) 2011-11-01
RS53182B (en) 2014-06-30
HK1132682A1 (en) 2010-03-05
ME01069B (me) 2012-10-20
PT1541137E (pt) 2010-05-17
PL1541137T3 (pl) 2010-07-30
HRP20100254T1 (hr) 2010-06-30
MY144053A (en) 2011-08-15
ES2340925T3 (es) 2010-06-11
SI1541137T1 (sl) 2010-06-30
CY1115064T1 (el) 2016-12-14
TWI257299B (en) 2006-07-01
SV2006001970A (es) 2006-02-16
TW200528073A (en) 2005-09-01
EP2138169A3 (en) 2011-04-06
EP2138169A2 (en) 2009-12-30
HRP20140077T1 (hr) 2014-02-28
EP1541137B1 (en) 2010-02-10
EP1541137A3 (en) 2005-11-16
CN101843603B (zh) 2012-06-27
CR8465A (es) 2007-06-06
UA89766C2 (en) 2010-03-10
DK1541137T3 (da) 2010-04-26
EP1541137A2 (en) 2005-06-15
HK1074801A1 (en) 2005-11-25
ES2445690T3 (es) 2014-03-04
DE602004025444D1 (de) 2010-03-25
CN101843603A (zh) 2010-09-29
RS51260B (sr) 2010-12-31
MY152750A (en) 2014-11-28
PT2138169E (pt) 2014-02-17
EP2138169B1 (en) 2013-11-06
HN2004000526A (es) 2010-02-01
ATE457168T1 (de) 2010-02-15
PE20051035A1 (es) 2006-02-08
DK2138169T3 (da) 2013-11-18
CY1110637T1 (el) 2015-04-29
GT200400262A (es) 2005-10-31
SI2138169T1 (sl) 2014-03-31
PL2138169T3 (pl) 2014-04-30

Similar Documents

Publication Publication Date Title
CR8465A (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
BR0312007A (pt) Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
MXPA04005211A (es) Sistemas terapeuticos transdermicos que contienen hormona esteroides y monocaprilato de propilenglicol.
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
AR021459A1 (es) PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS.
DE60318447D1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
PE20070119A1 (es) Nuevos regimenes para dispositivos de suministro controlado de farmacos para la anticoncepcion
UY28668A1 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
JO2492B1 (en) A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
CU20060121A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
DE69918124D1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam

Legal Events

Date Code Title Description
FC Refusal